A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis
Study CYC-202 is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of ST-0529 in subjects with moderately to severely active UC, defined as a score of 5 to 9 on the 3-Component Adapted Mayo Score (comprised of rectal bleeding, stool frequency and endoscopy sub-scores; score range 0-9).
100 Clinical Results associated with Sublimity Therapeutics HoldCo Ltd.
0 Patents (Medical) associated with Sublimity Therapeutics HoldCo Ltd.
100 Deals associated with Sublimity Therapeutics HoldCo Ltd.
100 Translational Medicine associated with Sublimity Therapeutics HoldCo Ltd.